rondecabtagene autoleucel
rondecabtagene autoleucel: developed by 1 company · 2 clinical trials tracked.
rondecabtagene autoleucel evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could rondecabtagene autoleucel → LYEL affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Lyell Immunopharma, Inc. (LYEL) Relapsed Non-Hodgkin Lymphoma; Large B-cell Lymphoma | Phase 1/Phase 2 |
Clinical Trials (2)
A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting CD19/CD20 CAR T-Cell Product Candidate, Vs. Investigator's Choice of CD19 CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma in the Second-line Setting
Primary endpoint: Event free survival
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of Rondecabtagene Autoleucel, a CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy in Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
Primary endpoint: Phase 1: Evaluate the safety and tolerability of a single dose of ronde-cel administered as a single agent
Frequently asked questions
Who is developing rondecabtagene autoleucel?
rondecabtagene autoleucel is being developed by Lyell Immunopharma, Inc..
How many clinical trials involve rondecabtagene autoleucel?
BioSniper tracks 2 clinical trials involving rondecabtagene autoleucel.